Literature DB >> 11487715

Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel.

M M Malingré1, W W Ten Bokkel Huinink, K Duchin, J H Schellens, J H Beijnen.   

Abstract

The objective of this study was to evaluate the pharmacokinetics of oral cyclosporin A (CsA) when co-administered to enhance the oral absorption of paclitaxel. Patients received oral paclitaxel in doses of 60-360 mg/m(2) in combination with a dose of oral CsA of 15 mg/kg. Dose escalation of paclitaxel from 60 to 300 mg/m(2) resulted in a significant decrease in the area under the concentration-time curve (AUC) of CsA from 24.4+/-9.9 to 17.6+/-2.8 mg/l.h (p=0.03) (n=28). In conclusion, increases in the paclitaxel dose resulted in a decrease in the AUC of CsA. This observation may be explained by the increase in the co-solvent Cremophor EL of paclitaxel causing reduced absorption of CsA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11487715     DOI: 10.1097/00001813-200108000-00005

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  3 in total

1.  Substrate-dependent effects of human ABCB1 coding polymorphisms.

Authors:  Jason M Gow; Laura M Hodges; Leslie W Chinn; Deanna L Kroetz
Journal:  J Pharmacol Exp Ther       Date:  2008-02-20       Impact factor: 4.030

2.  Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors.

Authors:  Shicheng Yang; R Neslihan Gursoy; Gregory Lambert; Simon Benita
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

3.  A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.

Authors:  S A Veltkamp; B Thijssen; J S Garrigue; G Lambert; F Lallemand; F Binlich; A D R Huitema; B Nuijen; A Nol; J H Beijnen; J H M Schellens
Journal:  Br J Cancer       Date:  2006-08-22       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.